PCI Biotech Holding ASA (FRA:4QG)
Germany flag Germany · Delayed Price · Currency is EUR
0.0170
-0.0002 (-1.16%)
At close: Jan 30, 2026

PCI Biotech Holding ASA Income Statement

Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Other Revenue
4.696.742.994.756.277.37
4.696.742.994.756.277.37
Revenue Growth (YoY)
-21.85%125.25%-37.05%-24.28%-14.86%-21.55%
Gross Profit
4.696.742.994.756.277.37
Selling, General & Admin
8.998.639.616.4420.613.92
Research & Development
17.3416.0615.6344.7671.7175.57
Operating Expenses
26.3224.6925.2361.292.389.49
Operating Income
-21.63-17.96-22.24-56.45-86.03-82.12
Interest Expense
-0.11-0.06-0.16-0.13-0.09-0.4
Interest & Investment Income
1.21.62.091.240.641.85
Currency Exchange Gain (Loss)
-----2.58.5
Other Non Operating Income (Expenses)
---00.24-0.41-0.07
Pretax Income
-20.54-16.42-20.32-55.1-88.39-72.24
Net Income
-20.54-16.42-20.32-55.1-88.39-72.24
Net Income to Common
-20.54-16.42-20.32-55.1-88.39-72.24
Shares Outstanding (Basic)
373737373737
Shares Outstanding (Diluted)
373737373737
Shares Change (YoY)
1.07%---0.11%-0.01%
EPS (Basic)
-0.55-0.44-0.54-1.48-2.37-1.94
EPS (Diluted)
-0.55-0.44-0.54-1.48-2.37-1.94
Free Cash Flow
-16.45-13.76-14.97-59.04-68.65-81.31
Free Cash Flow Per Share
-0.44-0.37-0.40-1.58-1.84-2.18
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-461.46%-266.59%-743.85%-1188.36%-1371.42%-1114.55%
Profit Margin
-438.10%-243.76%-679.43%-1159.89%-1409.07%-980.44%
Free Cash Flow Margin
-350.83%-204.28%-500.67%-1242.99%-1094.34%-1103.56%
EBITDA
-21.18-17.65-22.22-56.43-84.11-80.52
EBITDA Margin
--262.09%----
D&A For EBITDA
0.450.30.020.021.921.6
EBIT
-21.63-17.96-22.24-56.45-86.03-82.12
EBIT Margin
--266.59%----
Revenue as Reported
6.746.742.994.756.277.37
Source: S&P Global Market Intelligence. Standard template. Financial Sources.